Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alpine Immune Sciences Inc (ALPN)
NASDAQ:ALPN
Alpine Immune Sciences (ALPN) Stock Price & Analysis
438 Followers
ALPN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.71 - $64.57
Previous Close$64.46
Volume1.50M
Average Volume (3M)2.14M
Market Cap
$4.23B
Enterprise Value$3.91B
Total Cash (Recent Filing)$327.41M
Total Debt (Recent Filing)$9.91M
Price to Earnings (P/E)-93.1
Beta0.99
Next Earnings
May 09, 2024EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding65,546,136
10 Day Avg. Volume6,651,868
30 Day Avg. Volume2,136,487
Standard Deviation0.27
R-Squared0.05
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)12.89
Price to Sales (P/S)136.94
Price to Cash Flow (P/CF)-55.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue66.37
Enterprise Value/Gross Profit66.37
Enterprise Value/Ebitda-99.15
Forecast
1Y Price Target
$60.80Price Target Upside-5.69% Downside
Rating ConsensusHold
Number of Analyst Covering9
Alpine Immune Sciences News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressALPN's presentation of additional data at the World Congress of Nephrology highlights ongoing progress in clinical trials, potentially enhancing the drug's profile.
Drug EfficacyPovetacicept's superior tissue distribution and disease modifying properties, along with its significant reduction of disease parameters in lupus models, indicate a strong therapeutic potential.
Financial OutlookThe analyst's increased price target to $42 for ALPN reflects growing confidence in the drug's market potential and the strategic direction of the company.
Bears Say
Financial ImpactThe previously disclosed option exercise fee of $75 million has been reduced to $10 million, and the remaining pre-option development milestone has been removed.
Partnership Agreement ChangesALPN's revised agreement includes lower residual economics with partner ABBV.
Strategic ShiftsAnalyst interprets the recent disclosure as a strategic deprioritization of acazicolcept.
---
Ownership Overview
52.43% Insiders
9.06% Mutual Funds
11.88% Other Institutional Investors
26.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALPN FAQ
What was Alpine Immune Sciences Inc’s price range in the past 12 months?
Alpine Immune Sciences Inc lowest stock price was $6.71 and its highest was $64.57 in the past 12 months.
What is Alpine Immune Sciences Inc’s market cap?
Currently, no data Available
When is Alpine Immune Sciences Inc’s upcoming earnings report date?
Alpine Immune Sciences Inc’s upcoming earnings report date is May 09, 2024 which is in 19 days.
How were Alpine Immune Sciences Inc’s earnings last quarter?
Alpine Immune Sciences Inc released its earnings results on Mar 18, 2024. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of -$0.33 by $0.48.
Is Alpine Immune Sciences Inc overvalued?
According to Wall Street analysts Alpine Immune Sciences Inc’s price is currently Overvalued.
Does Alpine Immune Sciences Inc pay dividends?
Alpine Immune Sciences Inc does not currently pay dividends.
What is Alpine Immune Sciences Inc’s EPS estimate?
Alpine Immune Sciences Inc’s EPS estimate is -$0.44.
How many shares outstanding does Alpine Immune Sciences Inc have?
Alpine Immune Sciences Inc has 65,546,135 shares outstanding.
What happened to Alpine Immune Sciences Inc’s price movement after its last earnings report?
Alpine Immune Sciences Inc reported an EPS of $0.15 in its last earnings report, beating expectations of -$0.33. Following the earnings report the stock price went up 12.63%.
Which hedge fund is a major shareholder of Alpine Immune Sciences Inc?
Among the largest hedge funds holding Alpine Immune Sciences Inc’s share is RA Capital Management. It holds Alpine Immune Sciences Inc’s shares valued at 94M.
---
Alpine Immune Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$60.80 (-5.69% Downside)
$60.80 (-5.69% Downside)
Blogger Sentiment
Bullish
ALPN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 17.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $31.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.1%
Last 30 Days ▲ 27.5%
Last 30 Days ▲ 27.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
765.23%
12-Months-Change
Fundamentals
Return on Equity
-12.69%
Trailing 12-Months
Asset Growth
33.18%
Trailing 12-Months
Company Description
Alpine Immune Sciences Inc
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and TIP Program. The company was founded in 2015 and is headquartered in Seattle, WA.
---
ALPN Earnings Call
Q4 2024
0:00 / 0:00
---
ALPN Stock 12 Months Forecast
Average Price Target
$60.80
▼(-5.69% Downside)
Technical Analysis
Best Analysts Covering ALPN
1 Year
1 Year Success Rate
2/2 ratings generated profit
1 Year Average Return
+83.75%
assigned a buy rating last month
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +83.75% per trade.
---